All In Biotech

Drug Trial Radar · NCT04711252

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,371 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,371

Actual

Start

Jan 28, 2021

Primary completion

Jun 26, 2026

Study completion Feb 1, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.

Conditions

  • ER-Positive HER2-Negative Breast Cancer

Interventions

  • AZD9833Drug

    Dosage formulation: AZD9833 tablets will be administered orally

  • AnastrozoleDrug

    Dosage formulation: Anastrozole tablets will be administered orally.

  • Anastrozole placeboDrug

    Dosage formulation: anastrozole placebo tablets will be administrated orally.

  • AZD9833 placeboDrug

    Dosage formulation: AZD9833 placebo tablets will be administrated orally.

  • PalbociclibDrug

    Dosage formulation: palbociclib tablets/capsules will be administered orally

  • Luteinizing hormone-releasing hormone (LHRH) agonistDrug

    Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1Time frame: From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)

Locations

263 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Springdale, Arkansas

  • Research Site

    Harbor City, California

  • Research Site

    Solvang, California

  • Research Site

    Lone Tree, Colorado

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Hattiesburg, Mississippi

  • Research Site

    Omaha, Nebraska

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    West Columbia, South Carolina

  • Research Site

    Sioux Falls, South Dakota

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Tyler, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Kennewick, Washington

  • Research Site

    Renton, Washington

  • Research Site

    Morgantown, West Virginia

  • Research Site

    Feldkirch, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Sint-Niklaas, Belgium

Showing 40 of 263 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.